請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38784
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭永銘 | |
dc.contributor.author | Tsan-Hua Yu | en |
dc.contributor.author | 余燦華 | zh_TW |
dc.date.accessioned | 2021-06-13T16:46:06Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-15 | |
dc.identifier.citation | 1. Fava G. Molecular mechanisms of cholangiocarcinoma. World Journal of Gastrointestinal Pathophysiology 2010;1:12-22.
2. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51:vi1-vi9. 3. Aljiffry M, Walsh MJ and Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World Journal of Gastroenterology 2009;15:4240-4262. 4. Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y and Nagino M. The concept of perihilar cholangiocarcinoma is valid. British Journal of Surgery 2009;96:926-934. 5. Shaib Y and El-Serag HB. The epidemiology of cholangiocarcinoma. Seminars in Liver Disease 2004;24:115-125. 6. Shaib YH, Davila JA, McGlynn K and El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? Journal of Hepatology 2004;40:472-477. 7. McGlynn KA, Tarone RE and El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiology, Biomarkers and Prevention 2006;15:1198-1203. 8. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357. 9. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10. 10. Vauthey JN and Blumgart LH. Recent advances in the management of cholangiocarcinomas. Seminars in Liver Disease 1994;14:109-114. 11. Khan S, Thomas H, Davidson B and Taylor-Robinson S. Cholangiocarcinoma. Lancet 2005;366:1303-1314. 12. Parkin DM, Ohshima H, Srivatanakul P and Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiology, Biomarkers and Prevention 1993;2:537-544. 13. Khan SA. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of Hepatology 2002;37:806-813. 14. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, et al. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Modern Pathology 2009;22:182-190. 15. Sripa B and Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Current Opinion in Gastroenterology 2008;24:349-356. 16. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver fluke induces cholangiocarcinoma. PLoS Medicine 2007;4:1148-1155. 17. Sripa B. Pathobiology of opisthorchiasis: an update. Acta tropica 2003;88:209-220. 18. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S and Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Tropical Medicine and International Health 2004;9:588-594. 19. Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 2006;44:1025-1038. 20. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W, et al. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985;89:151-156. 21. Min HK. Clonorchis sinensis: pathogenesis and clinical features of infection. Arzneimittel-Forschung 1984;34:1151-1153. 22. Lim MK, Ju YH, Franceschi S, Oh JK, Kong HJ, Hwang SS, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. The American journal of tropical medicine and hygiene 2006;75:93-96. 23. Choi D, Lim JH, Lee KT, Lee JK, Choi SH, Heo JS, et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. Journal of hepatology 2006;44:1066-1073. 24. Belamaric J. Intrahepatic bile duct carcinoma and C. sinensis infection in Hong Kong. Cancer 1973;31:468-473. 25. Mitacek EJ, Brunnemann KD, Suttajit M, Martin N, Limsila T, Ohshima H, et al. Exposure to N-nitroso compounds in a population of high liver cancer regions in Thailand: volatile nitrosamine (VNA) levels in Thai food. Food and Chemical Toxicology 1999;37:297-305. 26. Haswell-Elkins MR, Satarug S, Tsuda M, Mairiang E, Esumi H, Sithithaworn P, et al. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. Mutation Research 1994;305:241-252. 27. Holzinger F, Z'Graggen K and Buchler MW. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Annals of oncology 1999;10 Suppl 4:122-126. 28. Shoda J, Tanaka N and Osuga T. Hepatolithiasis--epidemiology and pathogenesis update. Frontiers in Bioscience 2003;8:398-409. 29. Tetsuo O, Yasuhisa K, Masato K, Yukio F, Gen'ichi N, Takashi F, et al. Hepatolithiasis and intrahepatic cholangiocarcinoma. Kan, Tan, Sui 2002;45:295-301. 30. Koga A, Ichimiya H, Yamaguchi K, Miyazaki K and Nakayama F. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer 1985;55:2826-2829. 31. Sheen-Chen SM, Cheng YF, Chen FC, Chou FF and Lee TY. Ductal dilatation and stenting for residual hepatolithiasis: a promising treatment strategy. Gut 1998;42:708-710. 32. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World Journal of Gastroenterology 2008;14:632-635. 33. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes and Control 2001;12:959-964. 34. Chen MF, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC, et al. Intrahepatic cholangiocarcinoma in Taiwan. Journal of Hepato-Biliary-Pancreatic Surgery 1999;6:136-141. 35. Lee YM and Kaplan MM. Primary sclerosing cholangitis. New England Journal of Medicine 1995;332:924-933. 36. Schrumpf E and Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Practice and Research in Clinical Gastroenterology 2001;15:553-562. 37. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, Jr and LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Annals of Surgery 1991;213:21-25. 38. Welzel TM, Mellemkjaer L, Gloria1 G, Sakoda1 LC, Hsing1 AW, Ghormli1 LE, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. International Journal of Cancer 2006;120:638-641. 39. Summerfield JA, Nagafuchi Y, Sherlock S, Cadafalch J and Scheuer PJ. Hepatobiliary fibropolycystic diseases: A clinical and histological review of 51 patients. Journal of Hepatology 1986;2:141-156. 40. Dayton MT, Jr WPL and Tompkins RK. Caroli's disease: a premalignant condition? American Journal of Surgery 1983;145:41-48. 41. Chapman RW. Risk factors for biliary tract carcinogenesis. Annals of Oncology 1999;10:S308-S311. 42. Abbatt JD. History of the use and toxicity of thorotrast. Environmental Research 1979;18:6-12. 43. Zhu AX, Lauwers GY and Tanabe KK. Cholangiocarcinoma in association with Thorotrast exposure. Journal of Hepato-Biliary-Pancreatic Surgery 2004;11:430-433. 44. Nakanuma Y, Sripa B and Vatanasapt V. Pathology and Genetics of Tumours of the Digestive System. 2000;173-189. 45. Liu D, Momoi H, Li L, Ishikawa Y and Fukumoto M. Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma. International Journal of Cancer 2002;102:366-371. 46. Kojiro M, Sugihara S, Ito Y, Nakashima T, Ikezaki H, Mori T, et al. Pathomorphological study of thorotrast-related intrahepatic cholangiocarcinoma--a comparison with non-thorotrast cases. Japan journal of cancer clinics 1986;32:349-455. 47. Yamamoto Y, Usuda N, Takatsuji T, Kuwahara Y and Fukumoto M. Long incubation period for the induction of cancer by thorotrast is attributed to the uneven irradiation of liver cells at the microscopic level. Radiation Research 2009;171:494-503. 48. Kamikawa T, Amenomori M, Itoh T, Momoi H, Hiai H, Machinami R, et al. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. Radiation Research 1999;152:118-124. 49. Fukumoto M, Kuwahara Y, Ohkubo Y and Wang L. Analysis of carcinogenic mechanisms of liver cancers induced by chronic exposure to alpha-particles from internally deposited Thorotrast. Radiation Measurements 2006;41:1186-1190. 50. Chu KM, Lai ECS, Al-Hadeedi S, Arcilla CE, Jr., Lo CM, et al. Intrahepatic cholangiocarcinoma. World Journal of surgery 1997;21:301-306. 51. Okuda K, Kubo Y, Okazaki N, Arishima T and Hashimoto M. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977;39:232-246. 52. Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 2009;15:5976-5982. 53. Tao LY, Cai L, He XD, Liu W and Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. The American surgeon 2010;76:1210-1213. 54. DeGroen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM. Biliary tract cancers. New England Journal of Medicine 1999;341:1368-1378. 55. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. Journal of Hepato-Biliary-Pancreatic Surgery 2003;10:288-291. 56. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677. 57. Kang YK, Kim WH and Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Human Pathology 2002;33:877-883. 58. Serrano M, Hannon GJ and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707. 59. Ekholm SV. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Current Opinion in Cell Biology 2000;12:676-684. 60. Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Familial cancer 2007;6:453-461. 61. Lang JC, Borchers J, Danahey D, Smith S, Stover DG, Agrawal A, et al. Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. International journal of oncology 2002;21:401-408. 62. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Journal of the National Cancer Institute 2000;92:1260-1266. 63. Fargnoli MC, Chimenti S, Keller G, DalPozzo V, Soyer P, Hofler H, et al. p16(INK4a) and pl9(ARF) germline mutations in familial melanoma. Journal of Investigative Dermatology 1997;109:424-424. 64. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, et al. Germline P16 Mutations in Familial Melanoma. Nature Genetics 1994;8:15-21. 65. Liggett WH, Jr. and Sidransky D. Role of the p16 tumor suppressor gene in cancer. Journal of clinical oncology 1998;16:1197-1206. 66. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, et al. Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000;47:721-727. 67. Sugimachi K, Aishima Si, Taguchi Ki, Tanaka S, Shimada M, Kajiyama K, et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. Journal of Hepatology 2001;35:74-79. 68. Zen Y, Harada K, Sasaki M, Chen TC, Chen MF, Yeh TS, et al. Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-β1 by overexpression of cyclin D1. Laboratory Investigation 2005;85:572-581. 69. Vousden KH and Lu X. Live or let die: the cell's response to p53. Nature Reviews Cancer 2002;2:594-604. 70. Moll UM and Petrenko O. The MDM2-p53 interaction. Molecular Cancer Research 2003;1:1001-1008. 71. Miharaa M, Erstera S, Zaikaa A, Petrenkoa O, Chittendenb T, Pancoskac P, et al. p53 has a direct apoptogenic role at the mitochondria. Molecular Cell 2003;11:577-590. 72. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proceedings of the National Academy of Sciences of the United States of America 2003;100:8424-8429. 73. Solomon H, Brosh R, Buganim Y and Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discovery medicine 2010;9:448-454. 74. Kang YK, Kim WH, Lee HW, Lee HK and Kim YI. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Laboratory Investigation 1999;79:477-483. 75. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W and Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999;35:230-240. 76. Tannapfel A, Weinans L, Geibler F, Schutz A, Katalinic A, Kockerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Digestive Diseases and Sciences 2000;45:317-324. 77. Ryan KM, Phillips AC and Vousden KH. Regulation and function of the p53 tumor suppressor protein. Current Opinion in Cell Biology 2001;13:332-337. 78. Horie S, Endo K, Kawasaki H and Terada T. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows archiv 2000;437:25-30. 79. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K, et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998;33:145-153. 80. Park J, Tadlock L, Gores GJ and Patel T. Inhibition of interleukin 6–mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-1133. 81. Joplin R, Hishida T, Tsubouchi H, Daikuhara Y, Ayres R, Neuberger JM, et al. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. The Journal of clinical investigation 1992;90:1284-1289. 82. Matsumoto K, Fujii H, Michalopoulos G, Fung JJ and Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 1994;20:376-382. 83. Bottaro DP, Rubin JS, Faletto DL, Chan AML, Kmiecik TE, Vande-Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804. 84. Ma PC, Maulik G, Christensen J and Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer and Metastasis Reviews 2003;22:309-325. 85. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K and Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-278. 86. Terada T, Nakanuma Y and Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Human Pathology 1998;29:175-180. 87. Hynes NE and Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005;5:341-354. 88. Grant S, Liang Q and Paul D. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Frontiers in Bioscience 2002;7:376-389. 89. Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, et al. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocrine-related cancer 2009;16:565-572. 90. Heinemann V, Stintzing S, Kirchner T, Boeck S and Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer treatment reviews 2009;35:262-271. 91. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C and Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clinical cancer research 2009;15:4554-4560. 92. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-712. 93. Tada M, Omata M and Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Research 1990;50:1121-1124. 94. Bos JL. The ras gene family and human carcinogenesis. Mutation research 1988;195:255-271. 95. Wooster R, Futreal AP and Stratton MR. Sequencing analysis of BRAF mutations in human cancers. Methods in enzymology 2006;407:218-224. 96. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336. 97. Youle RJ and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008;9:47-59. 98. Charlotte F, L'Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. American Journal of Pathology 1994;144:460-465. 99. Guo LL, Xiao S and Guo Y. Detection of bcl-2 and bax expression and bcl-2/JH fusion gene in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 2004;10:3251-3254. 100. Cao Y and Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. Journal of Cellular Physiology 2002;190:279-286. 101. Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F, et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001;48:80-86. 102. Schmitz KJ, Lang H, Wohlschlaeger J, Reis H, Sotiropoulos GC, Schmid KW, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows archiv 2007;450:135-141. 103. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002;35:552-559. 104. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102:639-655. 105. Endo K, Ashida K, Miyake N and Terada T. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. Journal of Pathology 2001;193:310-317. 106. Hollingsworth MA and Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature Reviews Cancer 2004;4:45-60. 107. Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact. Oncology Reports 2009;22:649-657. 108. Xu HL, Inagaki Y, Seyama Y, Sugawara Y, Kokudo N, Nakata M, et al. Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion. Life Sciences 2009;85:395-400. 109. Boonla C, Sripa B, Thuwajit P, Cha-On U, Puapairoj A, Miwa M, et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 2005;11:4939-4946. 110. Ishikawa A, Sasaki M, Ohira S, Ohta T, Oda K, Nimura Y, et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Laboratory Investigation 2004;84:629-638. 111. Susumu A. Clinicopathological Features and Expression of Mucin Core Proteins (MUC1,MUC2,MUC3,MUC5AC), Carbohydrate Antigens (T, Tn and Sialosyl Tn), p53, WAF1, PCNA and Telomerase in Biliary Papillomatosis. Journal of the Juzen Medical Society 1999;108:628-641. 112. Suh KS, Chang SH, Lee HJ, Roh HR, Kim SH and Lee KU. Clinical outcomes and apomucin expression of intrahepatic cholangiocarcinoma according to gross morphology. Journal of the American College of Surgeons 2002;195:782-789. 113. Mignatti P and Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiological Reviews 1993;73:161-195. 114. Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N and Virimlioğlu K. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. Turkish Journal of Gastroenterology 2009;20:41-47. 115. Shirabe K, Shimada M, Kajiyama K, Hasegawa H, Gion T, Ikeda Y, et al. Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery 1999;126:842-846. 116. Leelawat K, Sompong S, Siriluck N and Jerasak W. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterology 2009;9. 117. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochemical Journal 1997;327:1-16. 118. Harada K, Masuda S, Hirano M and Nakanuma Y. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Human Pathology 2003;34:857-863. 119. Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor Necrosis Factor-α 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma. Neoplasia 2007;9:987-992. 120. Bosch FX, Ribes J and Borràs J. Epidemiology of primary liver cancer. Seminars in Liver Disease 1999;19:271-285. 121. Bosch FX, Ribes J, Díaz M and Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:5-16. 122. Beasley RP, Hwang LY, Lin CC and Chien CS. Hepatocellular carcinoma and hepatitis B virus : A Prospective Study of 22 707 Men in Taiwan. The Lancet 1981;318:1129-1133. 123. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62:8-17. 124. Zavitsanos X, Hatzakis A, Kaklamani E, Tzonou A, Toupadaki N and Broeksma C. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitis C virus peptides. Cancer Research 1992;52:5364-5367. 125. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A and Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997;112:184-187. 126. Idilman R, Maria ND, Colantoni A and Thiel DHV. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. Journal of Viral Hepatitis 1998;5:285-299. 127. Kew MC. Hepatitis viruses and human hepatocellular carcinoma. Yale Journal of Biology and Medicine 1997;70:119-125. 128. Kremsdorf D, Soussan P, Paterlini-Brechot P and Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006;25:3823-3833. 129. Blum HE and Moradpour D. Viral pathogenesis of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2002;3:413-420. 130. Benn J and Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proceedings of the National Academy of Sciences of the United States of America 1994;91:10350-10354. 131. Feitelson MA, Zhu M, Duan LX and London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-1117. 132. Vassilaki N, Khalili S and Mavromara P, HCV-associated hepatocellular carcinoma. Viral oncogenesis. 2006. 145-181. 133. Yamamoto M, Takasaki K, Nakano M and Saito A. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998;82:2145-2149. 134. Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H and Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. Journal of Hepato-Biliary-Pancreatic Surgery 1999;6:108-116. 135. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Japanese Journal of Cancer Research 2004;95:592-595. 136. Shaib YH, El-Serag HB, Davila JA, Morgan R and Mcglynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620-626. 137. Zhou HB, Wang H, Zhou DX, Wang H, Wang Q, Zou SS, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. European Journal of Cancer 2010;46:1056-1061. 138. Zhou HB, Wang H, Zhou DX, Wang H, Wang Q, Zou SS, et al. Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World Journal of Gastroenterology 2010;16:881-885. 139. Chen DS. Viral hepatitis in East Asia. Journal of the Formosan Medical Association 1996;95:6-12. 140. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL and Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. Journal of the Formosan Medical Association 2007;106:148-155. 141. Ivanov DB, Philippova MP and Tkachuk VA. Structure and functions of classical cadherins. Biochemistry (Mosc) 2001;66:1174-1186. 142. Haia S, Kuboa S, Yamamotoa S, Uenishia T, Tanakaa H, Shutoa T, et al. Clinicopathologic Characteristics of Hepatitis C Virus-Associated Intrahepatic Cholangiocarcinoma. Digestive Surgery 2005;22:432-439. 143. Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF and Hsieh SY. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. British Journal of Cancer 2009;100:1765-1770. 144. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 2008;52:224-232. 145. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000;88:2471-2477. 146. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. American Journal of Gastroenterology 2008;103:1716-1720. 147. Zhang Y, Bai X-F and Huang C-X. Hepatic stem cells: existence and origin. World Journal of Gastroenterology 2003;9:201-204. 148. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-3822. 149. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Japanese Journal of Cancer Research 2003;94:851-857. 150. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. American journal of surgery 2005;189:120-125. 151. Komuta M, Spee B, Vander BS, DeVos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008;47:1544-1556. 152. Steiner PE and Higginson J. Cholangiolocellular carcinoma of the liver. Cancer 1959;12:753-759. 153. Torbenson M, Wang J, Abraham S, Maitra A and Boitnott J. Bile ducts and ductules are positive for CD56 (N-CAM) in most cases of extrahepatic biliary atresia. American Journal of Surgical Pathology 2003;27:1454-1457. 154. Gütgemann I, Haas S, Berg JP, Zhou H, Büttner R and Fischer HP. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions. Virchows archiv 2006;448:407-411. 155. Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270-277. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38784 | - |
dc.description.abstract | 簡介:膽管癌是致命性癌症的一種,主要是因膽道上皮細胞癌化所造成。在全球胃腸道癌症病例中,膽管癌病例約佔了3%,若以肝臟惡性腫瘤而言,則估計有15%之多,排位僅次於肝細胞癌。膽管癌可大略的分成肝內膽管癌和肝外膽管癌兩類。在許多國家有很多關於引致肝內膽管癌的危險因子已經成功被證實並且在不同的結果間有其變異性。造成這些變異的情形,有可能是因為國家或區域間的地理、種族、飲食、年齡、環境、癌登系統和疾病分類不同所導致。已有許多流行病學上和分子表現的證據顯示肝寄生蟲、肝內結石、硬化性膽管炎、影像顯影劑Thorotrast的暴露等等是肝內膽管癌的危險因子。而病毒性肝炎與肝內膽管癌之關連性角色最近也被提出,但是直到現在為止,病毒性肝炎導致的肝內膽管癌在組織形態學上和基因性的特徵,仍然不清楚。我們在這研究分析了病毒性肝炎與肝內膽管癌臨床病理和分子表現的關聯。材料與方法:在2000至2010年期間,計有170位在國立台灣大學附設醫院追蹤治療和接受詳細病理評估的肝內膽管癌患者為本研究的研究對象。收集研究對象的臨床病理學資料和組織切片之組織形態學、分子表現、基因突變檢測資料,以進行分析。結果:在170位肝內膽管癌研究對象中,有69位(41%)是B 型和/或C型肝炎陽性患者。肝內膽管癌伴有病毒性肝炎患者較常發生在男性(68% vs. 42%, P=0.002)。而平均年齡則為肝內膽管癌伴有病毒性肝炎(57.88 ± 12.73 years)較無病毒性肝炎(62.14 ± 11.62 years)患者年輕約4歲(P=0.04)。至於血清AFP濃度在肝內膽管癌伴有病毒性肝炎患者有較多提高的情形,但血清CA19-9(OR=0.89, P=0.770)和CEA濃度(OR=1.13, P=0.750)並没有提高的情形。形態學上,肝內膽管癌伴有病毒性肝炎患者是較偏向mass-forming類型(R=3.52, P=0.027)和小膽管分化亞型(OR=2.71, P=0.008)。肝內膽管癌之N-cadherin表現是和感染病毒性肝炎高度相關(OR=5.06, P=0.0002)並且是唯一的獨立相關因子(Adjusted Odds Ratio=6.322, P=0.001)。使用N-cadherin 做為免疫化學染色標記,成功地識別出一群肝內膽管癌次分類。N-cadherin表現的肝內膽管癌患者之B型肝炎感染盛行率是75%,N-cadherin無表現的患者之B型肝炎感染盛行率是則僅有37%,N-cadherin表現是強烈和B型肝炎感染相關(P=0.0003)。表現N-cadherin的肝內膽管癌患者較為年輕,而且血清的AFP濃度較為提高(P=0.013),但是CA19-9(P=0.128)和CEA(P=0.155)之血清濃度則没有差別。另外,肝內膽管癌患者肝內結石病史則和N-cadherin表現負相關(P=0.003)。而N-cadherin表現的肝內膽管癌患者,形態上大部分是Mass-forming型(P=0.00002),呈小膽管分化組織形態(P=0.000003),Muc-2(P=0.000001)和CEA(P=0.0000005)不表現,同時K-RAS 也較没有發生突變(P=0.042)。結論:具膽管分化型和N-cadherin表現特徵的肝內膽管癌患者強烈和病毒性肝炎相關。 | zh_TW |
dc.description.abstract | INTRODUCTION: Cholangiocarcinoma is a lethal malignant tumor that arises from transformation of epithelial cells lining the bile ducts. Cholangiocarcinoma accounts for 3% of all gastrointestinal cancers and 15% of liver cancer worldwide and is the second most primary liver tumor following hepatocellular carcinoma. Cholangiocarcinoma is classified as intrahepatic and extrahepatic cholangiocarcinoma according to the location. Several risk factors of cholangiocarcinoma have successfully identified and the results are quite different in different countries. The phenomenon might be due to a variety of factors including geography, race, diet, environmental exposure, registration system, and different classification of disease among countries or areas. The most well known risk factors are liver fluke infestation, hepatolithiasis, sclerosing cholangitis, and Thorotrast exposure. The role of viral hepatitis in intrahepatic cholangiocarcinoma is recently emerging but until now the histomorphological and genetic features of viral hepatitis-associated intrahepatic cholangiocarcinoma is still unknown. In the study, we have analyzed the associated of viral hepatitis with clinicopathologic, histomorphological and molecular features of intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: From 2000 to 2010, 170 intrahepatic cholangiocarcinoma patients who received detailed pathological assessment and regular follow-up at the National Taiwan University Hospital were selected and formed the basis of this study. Clinicopathological features, histomorphology, molecular expression, and gene mutation from these tumors were collected and analyzed. RESULTS: Of 170 patients, 69 (41%) were positive for hepatitis B and/or C virus. Viral hepatitis-associated intrahepatic cholangiocarcinoma patients were more frequent in male (68% vs. 42%, P=0.002). The mean age of patients with viral hepatitis (57.88 ± 12.73 years) was approximately 4 years less than that of those without (62.14 ± 11.62 years). More intrahepatic cholangiocarcinoma patients with viral hepatitis had elevated serum AFP levels (OR=3.52, P=0.025), but the serum levels of CA19-9 (OR=0.89, P=0.770) and CEA (OR=1.13, P=0.750) were not different. Morphologically, viral hepatitis-associated intrahepatic cholangiocarcinoma was more likely to be of the mass-forming rather than the intraductal/periductal type (OR=3.52, P=0.027). Cholangiolar subtype was strongly associated viral hepatitis compared to the bile duct subtype of intrahepatic cholangiocarcinoma (OR=2.71, P=0.008). N-cadherin expression was highly correlated with viral hepatitis infection (OR=5.06, P=0.0002) and is the only independent factor associated with viral hepatitis (Adjusted Odds Ratio=6.322, P=0.001). Using N-cadherin as an immunohistochemical marker, we have successfully identified a subgroup of intrahepatic cholangiocarcinoma strongly associated with viral hepatitis. The prevalence of viral hepatitis in patients with N-cadherin positive was 75% and N-cadherin-negative patients was only 37%. Furthermore, patients with N-cadherin-positive intrahepatic cholangiocarcinoma were younger with elevated serum AFP levels (P=0.013), but the serum levels of CA19-9 (P=0.128) and CEA (P=0.155) were not statistically different. N-cadherin expression was significantly negative associated with intrahepatic lithiasis (P=0.003). Grossly, all these tumors were mass-forming type (P=0.00002). N-cadherin expression is associated with cholangiolar differentiation (P=0.000003), lack of CEA (P=0.0000005) and Muc-2 expression (P=0.000001), and K-RAS mutations were less frequent (P=0.042). CONCLUSION: A subgroup of intrahepatic cholangiocarcinoma characterized by cholangiolar differentiation and N-cadherin expression is strongly associated with viral hepatitis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:46:06Z (GMT). No. of bitstreams: 1 ntu-100-D94444003-1.pdf: 1768914 bytes, checksum: edcb9e479e6c70b8eff1d2b029970b7d (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | ABSTRACT IN ENGLISH--------------------------------------------------------------------------- 1
ABSTRACT IN CHINESE---------------------------------------------------------------------------- 4 Chapter 1 INTRODUCTION---------------------------------------------------------------------- 6 1.1 General introduction of cholangiocarcinoma----------------------------------------- 6 1.2 Incidence of CCA------------------------------------------------------------------------- 6 1.3 Risk factors of ICC----------------------------------------------------------------------- 7 1.3.1 Liver fluke infestation-------------------------------------------------------------------- 7 1.3.2 Nitroso-compounds----------------------------------------------------------------------- 9 1.3.3 Hepatolithiasis---------------------------------------------------------------------------- 9 1.3.4 Primary sclerosing cholangitis---------------------------------------------------------- 10 1.3.5 Caroli’s disease and choledochal cyst------------------------------------------------- 10 1.3.6 Thorotrast---------------------------------------------------------------------------------- 10 1.4 Clinical features of ICC------------------------------------------------------------------ 11 1.4.1 Symptom and sign------------------------------------------------------------------------ 11 1.4.2 Laboratory examination------------------------------------------------------------------ 11 1.5 Macroscopic classification of ICC----------------------------------------------------- 12 1.6 Genetic changes of ICC------------------------------------------------------------------ 13 1.6.1 Cell cycle related genes------------------------------------------------------------------ 13 1.6.2 Check point of cell cycle---------------------------------------------------------------- 14 1.6.3 Growth signal transduction pathway--------------------------------------------------- 15 1.6.4 Invasion and metastasis related genes------------------------------------------------- 17 1.7 The role of viral hepatitis in HCC------------------------------------------------------ 19 1.8 The role of viral hepatitis in ICC------------------------------------------------------- 21 Chapter 2 THE REASONS AND SPECIFIC AIMS------------------------------------------- 23 Chapter 3 MATERIALS AND METHODS----------------------------------------------------- 24 3.1 Subjects------------------------------------------------------------------------------------ 24 3.2 Immunohistochemical analysis--------------------------------------------------------- 24 3.3 Mutation analysis------------------------------------------------------------------------- 25 3.4 Statistical analysis------------------------------------------------------------------------ 27 Chapter 4 RESULTS--------------------------------------------------------------------------------- 28 4.1 Viral hepatitis is a risk factor for ICC-------------------------------------------------- 28 4.2 Clinicopathological features of viral hepatitis-associated ICC--------------------- 28 4.3 Viral hepatitis-associated ICC is strongly associated with cholangiolar differentiation----------------------------------------------------------------------------- 29 4.4 Viral hepatitis-associated ICC is strongly associated with N-cadherin expression---------------------------------------------------------------------------------- 31 4.5 N-cadherin expression is the best predictor for Viral hepatitis-associate ICC----------------------------------------------------------------------------------------- 31 4.6 N-cadherin positive ICCs have distinct clinicopathological features-------------- 31 4.7 K-RAS mutations were more frequently detected in N-cadherin negative tumors-------------------------------------------------------------------------------------- 33 4.8 CA19-9 was a prognostic factor for ICC---------------------------------------------- 34 Chapter 5 DISSCUSS-------------------------------------------------------------------------------- 35 5.1 Hepatitis-associated ICC is a distinct subtype of ICC------------------------------- 35 5.2 Hepatitis-related ICCs likely originated from bipotential hepatic progenitor cells----------------------------------------------------------------------------------------- 35 5.3 New morphology - cholangiolar type-------------------------------------------------- 37 5.4 CD56 is not an adequate marker for cholangiolar differentiation in ICC----------------------------------------------------------------------------------------- 37 5.5 A clue of ICC treatment----------------------------------------------------------------- 38 TABLES-------------------------------------------------------------------------------------------------- 39 Table 1 The difference in prevalence of hepatitis B/C between the subjects of this study compared with general population in Taiwan--------------------------------- 39 Table 2 Clinical features of hepatitis virus-associated and -unassociated ICCs------------ 40 Table 3 Clinicopathological significance of N-cadherin expression in resected ICCs---------------------------------------------------------------------------------------- 41 Table 4 Kaplan-Meier survival analysis of patients survival related with clinicopathological characteristic in ICCs--------------------------------------------- 43 Table 5 Multivariate Cox proportional hazards regression of patient survival related with clinicopathological characteristic in ICCs--------------------------------------- 45 FIGURES------------------------------------------------------------------------------------------------- 46 Figure 1 The scheme of difference in prevalence of hepatitis B/C between the subjects of the study and general population in Taiwan-------------------------------------- 46 Figure 2 Morphology of ICC with/without viral hepatitis------------------------------------ 47 Figure 3 N-cadherin expression in both nontumorous liver parenchyma and bile duct-- 48 Figure 4 Typical morphology and immunophenotype of viral hepatitis-related and -unrelated ICCs-------------------------------------------------------------------------- 49 Figure 5 N-cadherin expressed in ICCs--------------------------------------------------------- 51 Figure 6 N-cadherin expressed in ICCs--------------------------------------------------------- 52 Figure 7 Muc2 expressed in ICCs--------------------------------------------------------------- 53 Figure 8 N-cadherin expression is not associated with Muc1 expression in ICCs-------- 54 Figure 9 Mutation in the K-RAS gene---------------------------------------------------------- 55 Figure 10 Elevated serum CA19-9 level is significantly associated with lower 10 year survival rate------------------------------------------------------------------------------ 56 Figure 11 Elevated serum CA19-9 level is significantly associated with lower 10 year survival rate------------------------------------------------------------------------------ 57 Figure 12 The cholangiolar type had significantly higher 10 year survival rate than bile duct--------------------------------------------------------------------------------------- 58 REFERENCES------------------------------------------------------------------------------------------ 59 | |
dc.language.iso | en | |
dc.title | 肝炎相關膽管癌的臨床病理和分子分析 | zh_TW |
dc.title | The Clinicopathologic and Molecular Analysis of Hepatitis-associated Cholangiocarcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 吳建春,陳健弘,黃秀芬,袁瑞晃 | |
dc.subject.keyword | 肝內膽管癌,病毒性肝炎,臨床病理特徵,組織形態,分子表現, | zh_TW |
dc.subject.keyword | intrahepatic cholangiocarcinoma,viral hepatitis,clinicopathological features,histomorphology,molecular expression, | en |
dc.relation.page | 70 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。